Propanc CEO, James Nathanielsz Discusses the Company’s Groundbreaking Therapy, PRP, and its Potential to Revolutionize Cancer Treatment
NEW YORK, NY - 
(NewMediaWire) - December 12, 2023 - Propanc Biopharma, Inc. (QB - PPCB), is pleased to announce its CEO, James Nathanielsz, recently conducted an interview with SmallCapsDaily discussing the Company's recent developments, including the initiation of a Phase Ib study for their innovative pancreatic proenzyme therapy, PRP, highlighting its potential to transform cancer treatment. Nathanielsz shared insights into the company's goals, intellectual property strategy, and the positive patient outcomes observed during compassionate patient treatment, underscoring Propanc's commitment to advancing impactful solutions in the field of oncology.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (the "Company") is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian, and colorectal cancers. The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer.
For more information, please visit www.propanc.com.
To view the Company’s "Mechanism of Action" video on its anti-cancer lead product candidate, PRP, please click on the following link: http://www.propanc.com/news-media/video.
Contact Information
SmallCapsDaily
info@smallcapsdaily.com
View the original release on www.newmediawire.com
